The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MIRM | +61.41% | +232.11% | +27.13% | +447% |
| S&P | +12.33% | +84.73% | +13.06% | +124% |
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
It appears the FDA is willing to work with Mirium to get maralixibat approved as quickly as possible.
This newly public drug developer tripled its stock price in November following positive FDA news.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $133.01M | 47.2% |
| Gross Profit | $107.41M | 54.7% |
| Gross Margin | 80.75% | 3.9% |
| Market Cap | $3.68B | 97.9% |
| Market Cap / Employee | $10.37M | 0.0% |
| Employees | 355 | 0.0% |
| Net Income | $2.91M | 120.4% |
| EBITDA | $8.67M | 230.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $282.02M | 26.5% |
| Accounts Receivable | $107.13M | 56.3% |
| Inventory | 24 | 11.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $316.73M | 0.2% |
| Short Term Debt | $2.04M | 35.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -5.70% | 9.1% |
| Return On Invested Capital | -34.65% | 4.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $39.49M | 938.5% |
| Operating Free Cash Flow | $39.68M | 896.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.55 | 9.65 | 10.79 | 14.38 | 77.51% |
| Price to Sales | 5.90 | 5.81 | 5.90 | 8.86 | 45.91% |
| Price to Tangible Book Value | -83.44 | -90.06 | -237.66 | 212.27 | -475.05% |
| Price to Free Cash Flow TTM | 213.07 | 293.33 | 94.28 | - | |
| Enterprise Value to EBITDA | -111.52 | -245.53 | 2385.14 | 475.64 | -266.24% |
| Free Cash Flow Yield | 0.5% | 0.3% | 1.1% | - | |
| Return on Equity | -37.1% | -33.1% | -24.2% | -15.8% | -59.29% |
| Total Debt | $317.76M | $317.16M | $318.90M | $318.76M | 0.35% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
